Har­vard’s Aaron Kessel­heim re­signs from ex­pert pan­el in wake of ad­u­canum­ab OK, blast­ing FDA for ‘worst drug ...

4 years ago
FDA+

Ver­tex strikes out on its lat­est big shot at a rare ge­net­ic dis­ease. But they're go­ing to keep on swing­ing

4 years ago
R&D

Covid-19 man­u­fac­tur­ing roundup: BioN­Tech an­nounces plans to pro­duce mR­NA vac­cines in Africa; As­traZeneca de­liv­er­ies ...

4 years ago
Coronavirus
Manufacturing

An API firm with a his­to­ry of J&J fund­ing scores a ma­jor loan to ad­vance its port­fo­lio

4 years ago
R&D
Manufacturing

With its con­tro­ver­sial ad­u­canum­ab ap­proval in hand, Bio­gen gears up for a quick US roll­out

4 years ago
R&D
Manufacturing

A Wash­ing­ton CMO is dou­bling its man­u­fac­tur­ing ca­pac­i­ty, less than 5 years in­to its ex­is­tence

4 years ago
Manufacturing

Ex­e­lead inks deal to man­u­fac­ture lipid nanopar­ti­cles for Pfiz­er/BioN­Tech vac­cine

4 years ago
Outsourcing
Manufacturing

No­var­tis cuts jobs at Swiss plant as a UK fa­cil­i­ty sits in a hold­ing pat­tern with 200 po­si­tions on the line — ...

4 years ago
Outsourcing
Manufacturing

Verona signs Chi­na deal for PhI­II COPD drug; Te­va con­tin­ues le­gal bat­tle with Eli Lil­ly, al­leg­ing new patent ...

4 years ago
News Briefing

A sec­ond ad­comm mem­ber aban­dons his post in af­ter­math of con­tro­ver­sial ad­u­canum­ab de­ci­sion

4 years ago
Pharma
FDA+

Bris­tol My­er­s' CAR-T Breyanzi busts out a win in ear­li­er-line lym­phoma, po­ten­tial­ly crack­ing open an ex­pand­ed mar­ket

4 years ago
R&D
Pharma

Ju­bi­lant Hol­lis­ter­Sti­er plots out ex­pan­sion at WA ster­ile in­jecta­bles plant amid work on Covid-19 vac­cines

4 years ago
Outsourcing
Manufacturing

AGC adds an­oth­er ma­jor Covid-19 vac­cine mak­er to the client list with BioN­Tech pact for plas­mid DNA

4 years ago
R&D
Manufacturing

FDA plans new stud­ies on ac­cel­er­at­ed ap­proval dis­clo­sures in bio­phar­ma ads

4 years ago
FDA+

Covid-19 roundup: Mod­er­na has filed for vac­cine use in chil­dren; Claim­ing lead­er­ship to com­bat Covid-19, US pledges ...

4 years ago
Coronavirus

Ver­sant-backed Bright Peak sets a date to bring its IL-2 in­to the clin­ic — but all eyes are on an IPO af­ter lat­est ...

4 years ago
Financing

Syn­thekine nabs megaround in bid to edge out Mer­ck, Sanofi in IL-2 sprint

4 years ago
Financing

The Flag­ship train keeps chug­ging with its 'in­ter­sys­tem­s' play­er eye­ing the clin­ic next year with 3 new drugs

4 years ago
Financing

Sid Mukher­jee's Vor taps a CAR-T de­vel­op­ment part­ner to strap to its at­tempt at bet­ter stem cell trans­plants

4 years ago
Deals
Cell/Gene Tx

A Medicxi-backed start­up looks to tack­le treat­ment-re­sis­tant blood can­cers, and it's go­ing af­ter AML first

4 years ago
Financing
Startups

Cit­ing 'ex­ces­sive' ex­ec­u­tive com­pen­sa­tion, ad­vi­so­ry firms want a long­time Re­gen­eron board mem­ber oust­ed

4 years ago
People
Pharma

UP­DATE: Will Bio­gen ever pub­lish the tri­al re­sults for its new Alzheimer’s drug?

4 years ago
Pharma
FDA+

What does a clear ma­jor­i­ty of the bio­phar­ma in­dus­try think of the FDA ap­proval of ad­u­canum­ab? 'Hor­ri­fy­ing' ...

4 years ago
Pharma

FDA dips its toe in­to the world of pa­tient-re­port­ed out­comes for can­cer tri­als

4 years ago
R&D
FDA+
First page Previous page 691692693694695696697 Next page Last page
A service from the Financial Times